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The immune system acts to protect the host against pathogenic invaders. However, components
of the immune system can become dysregulated such that their activities are directed against host
tissues, so causing damage. Lymphocytes are involved in both the beneficial and detrimental
effects of the immune system. Both the level of fat and the types of fatty acid present in the diet
can affect lymphocyte functions. The fatty acid composition of lymphocytes, and other immune
cells, is altered according to the fatty acid composition of the diet and this alters the capacity of
those cells to produce eicosanoids, such as prostaglandin E2, which are involved in
immunoregulation. A high fat diet can impair lymphocyte function. Cell culture and animal
feeding studies indicate that oleic, linoleic, conjugated linoleic, g-linolenic, dihomo-g-linolenic,
arachidonic, a-linolenic, eicosapentaenoic and docosahexaenoic acids can all influence
lymphocyte proliferation, the production of cytokines by lymphocytes, and natural killer cell
activity. High intakes of some of these fatty acids are necessary to induce these effects. Among
these fatty acids the long chain n-3 fatty acids, especially eicosapentaenoic acid, appear to be the
most potent when included in the human diet. Although not all studies agree, it appears that fish
oil, which contains eicosapentaenoic acid, down regulates the T-helper 1-type response which is
associated with chronic inflammatory disease. There is evidence for beneficial effects of fish oil
in such diseases; this evidence is strongest for rheumatoid arthritis. Since n-3 fatty acids also
antagonise the production of inflammatory eicosanoid mediators from arachidonic acid, there is
potential for benefit in asthma and related diseases. Recent evidence indicates that fish oil may be
of benefit in some asthmatics but not others.
Fatty acid: Fish oil: Lymphocyte: Monocyte: Cytokine: Eicosanoid: Inflammation:
Immunity
Introduction
Interest in the effects of fatty acids upon the immune system
dates back many years, but this interest intensified with the
elucidation of the roles of eicosanoids derived from
arachidonic acid (ARA; 20:4n-6) in modulating inflam-
mation and immunity and with the knowledge that the
metabolism of ARA to yield these mediators can be
inhibited by the long chain n-3 polyunsaturated fatty acids
(PUFA) found in fish oils. This article will review the
effects of fatty acids upon lymphocyte proliferation,
lymphocyte-mediated cytotoxicity, lymphocyte-derived
cytokine production, antibody production, and cell-
mediated immunity. Since lymphocytes are activated in
vivo by presentation of antigen by antigen-presenting cells
and by cytokines derived from them, this review will also
describe the effects of fatty acids on these processes. These,
and other, aspects of fatty acids and immunity have been
reviewed a number of times (Calder, 1995, 1996a,b, 1997,
1998a,b,c, 1999; Blok et al. 1996; Alexander, 1998;
Grimble, 1998; Harbige, 1998; Hughes, 1998; Miles &
Calder, 1998; Sperling, 1998; Wu & Meydani, 1998;
Yaqoob, 1998a,b) and the reader is referred to these articles
for a more complete overview of the field. Mechanisms by
which fatty acids might influence the functions of
lymphocytes, apart from effects upon eicosanoid pro-
duction, will not be reviewed here; these have been
discussed elsewhere (Calder 1996b; Miles & Calder 1998;
Yaqoob, 1998b).
Lymphocytes
Lymphocytes are the cells that specifically recognise and
respond to foreign antigens and, as such, they form the core
of the acquired (or specific) immune system. They are
* Corresponding author: Dr P. C. Calder, fax 44 (0) 23 8059 4383, email pcc@soton.ac.uk
† Present address: Hugh Sinclair Unit of Human Nutrition, School of Food Biosciences, University of Reading, Whiteknights, Reading RG6 6AP, UK
Abbreviations: EPA, eicosapentaenoic acid; ARA, arachidonic acid; PUFA, polyunsaturated fatty acid; GLA, g-linolenic acid; DGLA, di-homo-g-linolenic
acid; ALNA, a-linolenic acid; DHA, docosahexaenoic acid; NK, natural killer; Th-lymphocyte, helper T-lymphocyte; CTL, cytotoxic T-lymphocyte;
MHC, major histocompatibility complex; DTH, delayed type hypersensitivity; MNC, mononuclear cell.
British Journal of Nutrition (2002), 87, Suppl. 1, S31–S48 DOI: 10.1079/BJN2001455
q The Authors 2002
https://doi.org/10.1079/BJN2001455
Downloaded from https:/www.cambridge.org/core. Reading University, on 23 Jan 2017 at 16:51:54, subject to the Cambridge Core terms of use, available at https:/www.cambridge.org/core/terms.
present as circulating cells in blood and lymph, as
anatomically defined collections of cells in lymphoid
organs (thymus, spleen, lymph nodes, gut-associated
lymphoid tissue) or as scattered cells in other tissues.
Lymphocytes exist as distinct subsets that are quite different
in their functions and protein products, although they are
morphologically fairly similar. The principal types of
lymphocytes are T- and B-lymphocytes and natural killer
(NK) cells.
T-lymphocytes
The precursors of T-lymphocytes arise in the bone marrow
and mature in the thymus. T-lymphocytes are further
subdivided into functionally distinct populations, the best
defined of which are helper T-lymphocytes (Th-lympho-
cytes) and cytotoxic T-lymphocytes (CTL); these classes of
T-lymphocyte are characterised by the presence of CD4 or
CD8 molecules, respectively, on their surface. T-lympho-
cytes recognise peptide antigens attached to major
histocompatibility complex (MHC) proteins on the surface
of so-called antigen presenting cells. MHC II is expressed
on dendritic cells, monocytes and macrophages, and
B-lymphocytes. The role of MHC II is the presentation of
antigenic peptides derived from intracellular proteins of
exogenous origin to the T-cell receptor-CD3 complex on
CD4+ (Th) lymphocytes (Fig. 1). MHC I is expressed on
most cells, but the level of expression varies among
different cell types. The role of MHC I is the presentation of
antigenic peptides derived from intracellular proteins of
endogenous origin to the T-cell receptor-CD3 complex on
CD8+ lymphocytes (CTL). Thus, the MHC I-CTL
interaction is involved in the destruction of cells infected
with viruses. The MHC-T-cell receptor interaction on its
own is insufficient to promote T-lymphocyte activation
even in the presence of CD4 or CD8; other interactions
Fig. 1. The interaction between antigen presenting cells and T-lymphocytes. In
the example shown, an extracellular pathogen is recognised and phagocytosed
by an antigen presenting cell; this process is enhanced by coating of the patho-
gen with complement or antibodies (not shown). The phagocytic vesicle contain-
ing the pathogen fuses with a lysosome and the pathogen is subsequently
digested. Peptides from the pathogen associate with MHC II and are trans-
located to the cell surface. The peptide is presented to the T-cell receptor on the
T-lymphocyte surface. The interaction between MHC II and the T-cell receptor is
stabilised by CD4 (CD8 stabilises the interaction between MHC I and the T-cell
receptor), while accessory molecules on the surface of each cell (e.g. B7 and
CD28) interact to provide further stability. CD3 tranduces signals from the T-cell
receptor into the T-lymphocyte. Both the antigen presenting cell and the T-lym-
phocyte secrete cytokines to influence the activities of one another.
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between molecules on the surface of the antigen presenting
cell and the T-cell are required (e.g. B7 and CD28). These
molecules are termed accessory molecules.
In response to stimulation T-lymphocytes secrete
cytokines whose function is to promote an increase in
T-lymphocyte number (termed lymphocyte proliferation),
the differentiation of T-lymphocytes and the activation of
other cell types including B-lymphocytes, NK cells and
macrophages.
The Th-lymphocytes are further sub-divided according to
the pattern of cytokines they produce (Fig. 2). Upon initial
encounter with antigen naive Th-cells produce mainly
interleukin-2 (IL-2). These cells may differentiate into a
population sometimes referred to as Th0 cells which
differentiate further into either Th1 or Th2 cells (Fig. 2); this
is a simplistic view and it is now recognised that there are
most likely other classes of Th cell (e.g. Th3) (Mossmann &
Sad, 1996). The differentiation into Th1 or Th2 is regulated
by cytokines: IL-12 and IFN-g promote the development of
Th1 cells, while IL-4 promotes the development of Th2 cells
(Fig. 2). Th1 and Th2 themselves have relatively restricted
profiles of cytokine production: Th1 cells produce IL-2 and
IFN-g which activate macrophages, NK cells and CTL
and are the principal effectors of cell-mediated immunity
and delayed type hypersensitivity (DTH). Intracellular
pathogens tend to induce Th1 activity. This is because
antigen presenting cells are a major source of IL-12. Thus,
infection with intracellular pathogens will promote
differentiation along the Th1 pathway, and this will in
turn produce cytokines which promote the activity of cells
able to destroy such pathogens (e.g. macrophages, CTL, NK
cells) and the immunoglobulin (Ig) G-type of antibody
response (Fig. 2). Th2 cells produce IL-4, which stimulates
IgE production, IL-5, an eosinophil activating factor, and
IL-10, which together with IL-4 suppresses cell-mediated
immunity and inflammation (Fig. 2). Infection with
extracellular pathogens, such as helminthic worms, tends
to induce differentiation along the Th2 pathway, and this
will in turn induce responses which are able to destroy such
pathogens, e.g. IgE production (Fig. 2). One important
aspect of the Th1–Th2 paradigm is that Th1-type cytokines,
especially IFN-g, inhibit the differentiation of Th2 cells,
while Th2-type cytokines, especially IL-4, inhibit the
differentiation of Th1 cells, Fig. 2 (Mossmann & Sad,
1996).
B-lymphocytes
B-lymphocytes mature in the bone marrow. They are the
cells responsible for producing antibodies. The role of these
antibodies is to neutralise and promote elimination of the
antigen that induced their formation (Fig. 2). The antibodies
produced belong to different Ig classes depending upon the
type of stimulus and the anatomical site of the lymphocytes
involved. Cytokines determine the types of antibodies
produced by selectively promoting Ig heavy chain class
switching and by stimulating B-lymphocyte proliferation.
The most potent cytokines involved in B-lymphocyte
activation are those produced by Th cells (Fig. 2).
NK cells
These are a class of lymphocyte which do not express
surface markers identifying them as either T- or
B-lymphocytes. They are capable of lysing tumour or
virus-infected cells and have a role in graft rejection. NK
cells are activated by IL-2, IL-12, IFN-g and tumour
necrosis factor (TNF)-a.
Lymphocytes in health and disease
Clearly a well functioning immune system is essential to
health. It serves to protect the host from the effects of ever
present pathogenic organisms. Cells of the immune system
also have a role in identifying and eliminating cancer cells.
There are however some detrimental effects of the immune
system and lymphocytes are central to these effects. First, in
the course of its activity to recognise and eliminate foreign
antigens, the immune system is responsible for the rejection
of transplanted tissues. Second, in some individuals the
immune system appears to recognise host antigens as ‘non-
self’ rather than as ‘self’. As a result, an immune response to
host tissues is generated and this leads to tissue damage.
This is the characteristic of so-called chronic inflammatory
or autoimmune diseases. Such diseases are linked to genes
coding for proteins involved in antigen presentation or
recognition such as the MHC II proteins and the T-cell
receptor; thus there is a genetic predisposition to these
diseases. These diseases are typified by an ongoing chronic
inflammation involving the pro-inflammatory cytokines
produced by monocytes and macrophages and by a
dysregulated Th1 lymphocyte response. Examples of this
type of disease include rheumatoid arthritis, type-1 diabetes,
Crohn’s disease, psoriasis, and multiple sclerosis. Third, the
immune system of some individuals can become sensitised
to usually benign antigens from the environment and can
respond inappropriately to them by the release of IgE. Such
antigens can include components of foods or of so-called
allergens (e.g. cat or dog fur, house dust mite, some
pollens), such that this response can lead to allergies, asthma
and related atopic diseases. Although these diseases are also
termed chronic inflammatory diseases they have a different
immune basis from the diseases described above, although
again they are typified by inappropriate recognition of and/
or responses to antigens. However, atopic diseases are
characterised by a dysregulated Th2 lymphocyte response
such that excessive amounts of IL-4, IL-5 and IL-10 are
found. IL-10 suppresses the Th1 response, IL-4 stimulates
IgE production by B-lymphocytes (IgE promotes histamine
release from mast cells), and IL-4 and IL-5 activate
eosinophils which are involved in the persistent inflam-
mation which is a characteristic of these diseases.
Assessment of the effect of fatty acids on lymphocyte
function
General considerations
There is a wide range of methodologies available by which
to assess the impact of fatty acids on specific lymphocyte
functions. In vitro studies adding pure fatty acids, fatty acid
mixtures or other lipids (e.g. triacylglycerols, phospholipids,
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Fig. 2. The differentiation and roles of Th1 and Th2 lymphocytes. ! indicates produces; !||| indicates regulates.
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lipoproteins) to lymphocytes in culture can be used; these
studies use conditions which are highly controlled, although
they are often rather unphysiological in nature. For example,
the cells are cultured in isolation from the other types of cells
with which they would come into contact in the body and the
concentrations of fatty acids added to the cultures are often
greatly in excess of those which can be attained in vivo. The
effects of changing the amounts or types of fat in the diet on
lymphocyte functions can be studied by isolating lympho-
cytes from animals or humans which have undergone dietary
changes and culturing them ex vivo. While this has some of
the disadvantages of the pure in vitro approach, its controlled
nature allows effects on specific cell types and functions to be
assessed and allows the exploration of the mechanisms
underlying functional changes. One solution to the problem
of using isolated lymphocytes in culture has been the
development of whole blood culture systems (e.g. Yaqoob
et al. 1999), which have been used in some studies
investigating the influence of dietary fatty acids in animals
(Yaqoob et al. 1995) and humans (Yaqoob et al. 2000).
Clearly one limitation to the isolation and subsequent culture
of lymphocytes is having a suitable source. For animal
studies this does not represent a problem and lymphocytes
from the bloodstream, spleen, thymus, lymph nodes, lungs
and gut-associated lymphoid tissue are accessible and have
been studied. However, most human studies have been
restricted to using blood lymphocytes, often as a mixture with
monocytes. Preparations containing such mixtures of
lymphocytes and monocytes are often described as
mononuclear cell (MNC) preparations; typically a MNC
preparation from human peripheral blood would comprise
85–90 % lymphocytes and 10–15 % monocytes. One other
important difference between dietary experiments in animals
and humans is that animal experiments have often used very
high amounts of the fatty acids under investigation and these
represent intakes that could never be achieved in humans.
While the use of such dietary regimens means that effects can
be established and mechanisms studied, it is important that
the effects of fatty acids at levels in the animal diet relevant to
human consumption be demonstrated and that effects be
determined in humans under appropriate conditions.
Measures using isolated cells
Probably the most widely used indicator of lymphocyte
function is proliferation, i.e. the ability of the cells to divide
when stimulated. Most often this is measured as the
incorporation of radioactively-labelled thymidine into the
DNA of the dividing lymphocytes, although a number of
other measures are available. Agents used to stimulate
lymphocyte proliferation include mitogens like concanava-
lin A (Con A) and phytohaemagglutinin (PHA), which
stimulate T-lymphocytes, pokeweed mitogen, which stimu-
lates a mixture of T- and B-lymphocytes, and bacterial
lipopolysaccharide (LPS), which stimulates B-lymphocytes
(and also monocytes). T-lymphocyte proliferation can also
be triggered by using antibodies to CD3 or to CD3 in
combination with antibodies to other surface proteins (e.g.
CD4) or by a combination of agents which stimulate protein
kinase C and a rise in the intracellular free calcium
concentration. If the animal or individual has been
sensitised to an antigen (or allergen) then the antigen (or
allergen) can be used to stimulate lymphocyte proliferation.
The proliferative response to the antigen or allergen will be
much smaller than the response to mitogens or antibodies,
since the antigenic response is specific, targeting only those
T-lymphocytes which recognise the antigen; in contrast
mitogenic stimulation is non-specific and will target a large
proportion, perhaps all, of T- or B-lymphocytes in the cell
preparation. In response to stimulation with mitogen,
antibodies, antigen or allergen, lymphocytes will produce
cytokines (e.g. IL-2, IFN-g, IL-4, IL-10, IL-6) and the
concentrations of these can be measured. LPS stimulation of
monocytes, macrophages or MNC leads to production of
TNF-a, IL-1 and IL-6. B-lymphocytes produce Ig in culture
and the total concentration of particular Ig classes (e.g. IgG)
can be measured, as can the concentration of Ig for a specific
antigenic (or allergenic) stimulus. The cell surface
expression of molecules involved in cell–cell interaction
(e.g. adhesion molecules), in antigen presentation (e.g.
MHC II) and in cellular activation (e.g. cytokine receptors)
can be measured, as can the ability of antigen presenting
cells to present antigen to sensitised T-lymphocytes. NK
cell and CTL activity can be measured as the killing of
tumour cells or virally-infected cells known to be specific
targets for these cells.
In vivo measures
The effects of changing the amounts or types of fat in the
diet can also be studied by assessing certain indicators of
lymphocyte function in vivo, particularly in response to an
immunological challenge. Clearly, animals offer greater
access to the immune system, but it is important that
observations made in animal studies be confirmed in
humans. The number, types and percentages of lymphocytes
circulating in the bloodstream and the cell surface
expression of molecules involved in cell–cell interaction,
antigen presentation, and cellular activation can be
measured using staining procedures. The size and cellularity
(the numbers and types of cells present) of lymphoid organs
can be determined. In animal studies the thymus, spleen,
lymph nodes and some components of the gut-associated
lymphoid tissue can be removed and weighed. In human
studies thymus size can be estimated by imaging techniques.
The concentrations of total Ig and of the Ig subclasses in the
bloodstream can be measured, as can the circulating
concentrations of Ig specific for antigens after an antigen
challenge or vaccination. Secretory IgA (sIgA) is found in
extracellular fluids and its concentration in saliva, tears and
intestinal washings can be measured. Circulating concen-
trations of cytokines and soluble cytokine receptors can be
measured. The overall cell-mediated immune response can
be determined by assessing responses to challenges known
to involve T-lymphocytes. For example, the DTH response
to intradermal application of an antigen to which the
individual has already been exposed has been used in some
human studies; the response is measured as the size of the
swelling (termed induration) around the area of application
at a period (usually 48 h) after the application. In animal
studies the ability to reject grafted tissues, especially skin,
has been used.
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Variation in lymphocyte responses
Variation in cellular responses among individuals is not a
great problem in animal studies since these most often use
inbred strains. However, it is important to note that any
particular response will differ among animal species and
even among different strains within a species (Table 1). It is
highly likely that immune cells from different species and
strains will exhibit different sensitivities to the amount of fat
in the diet and to different types of dietary fatty acids. Thus,
extrapolations from animal studies to humans should be
made cautiously.
There is wide variation in lymphocyte responses among
healthy human subjects (Table 2). This is in part related to
genetic polymorphisms which regulate the expression of
cytokines, cytokine receptors, MHC II (in humans this is
termed human leucocyte antigen or HLA), adhesion
molecules and so on. However, other factors such as age,
gender, smoking habits, habitual levels of exercise, alcohol
consumption, diet, stage in the female menstrual cycle, and
history of infections and vaccinations are likely to be
important contributors to the observed variation. Consider-
ation of this variation is important when designing and
interpreting human studies. It is not clear whether there is
variation in responsiveness of human lymphocytes to the
effects of dietary fatty acids, although one study suggests
that among women this varies with age (Meydani et al.
1991).
Eicosanoids: a link between fatty acids and lymphocyte
functions
Eicosanoids
Eicosanoids are a group of chemical messengers synthesised
from the 20-carbon PUFA dihomo-g-linolenic acid (DGLA;
20:3n-6), ARA and eicosapentaenoic acid (EPA; 20:5n-3).
Eicosanoids include prostaglandins (PG), thromboxanes
(TX), leukotrienes (LT), lipoxins, hydroperoxy-eicosate-
traenoic acids and hydroxyeicosatetraenoic acids (HETE).
The fatty acid precursor for eicosanoid synthesis is released
from cell membrane phospholipids, usually by the action of
phospholipase A2 activated in response to a cellular
stimulus. Because the membranes of most cells contain
large amounts of ARA, compared with DGLA and EPA,
ARA is usually the principal precursor for eicosanoid
synthesis and gives rise to the 2-series PG and TX and the
4-series LT (Fig. 3). PG and TX are produced by the
cyclooxygenase enzymes (COX 1 and COX 2), while LT
and related compounds are produced by lipoxygenase
enzymes (LOX) of which there are three types (5-, 12- and
15-LOX). Lymphocytes are poor sources of eicosanoids
(Goldyne, 1988), although they are subject to regulation by
them. PGE2 inhibits lymphocyte proliferation, NK cell
activity and the production of Th1 cytokines (IL-2, IFN-g)
(see Kinsella et al. 1990; Roper & Phipps, 1994 for
reviews). PGE2 also inhibits MHC II expression and the
production of TNF-a and IL-1b by monocytes and
macrophages (see Kinsella et al. 1990; Roper & Phipps,
1994). In contrast, PGE2 does not appear to directly
influence the production of the Th2 cytokine IL-4 and
promotes IgE production by B-lymphocytes (see Roper &
Phipps, 1994). LTB4 enhances production of TNF-a, IL-1
and IL-6 by monocytes and macrophages, enhances Th1
cytokine production and enhances NK cell activity (see
Kinsella et al. 1990; Lewis et al. 1990 for reviews). Thus,
ARA gives rise to mediators with opposing actions.
Therefore, the overall effect will depend upon the timing
of production of the different eicosanoids and upon the
sensitivity of target cells to the concentrations of the
different eicosanoids produced.
g-Linolenic acid and eicosanoids
g-Linolenic acid (GLA; 18:3n-6) is found in borage,
blackcurrant seed and evening primrose oils where it
contributes about 20–25 %, 15–20 % and 5–10 % of fatty
acids, respectively. Apart from the presence of GLA, these
oils tend to resemble typical n-6 PUFA-rich vegetable oils
with a high content of linoleic acid (18:2n-6), although
blackcurrant seed oil also contains a-linolenic acid (ALNA;
18:3n-3). GLA does not accumulate in cell membranes,
even when it is provided in the diet (Rossetti et al. 1997;
Yaqoob et al. 2000). Instead, the content of its derivative,
DGLA, is increased (Rossetti et al. 1997; Johnson et al.
1997; Yaqoob et al. 2000) (Table 3). The significance of this
is that DGLA is a substrate for COX, giving rise to the
1-series PG (e.g. PGE1), for 5-LOX giving rise to 3-series
LT and for 15-LOX, giving rise to 15-hydroxy-DGLA
(Fig. 3). Like PGE2, PGE1 inhibits IL-2 and IFN-g
production by lymphocytes (Gold et al. 1994), inhibits
lymphocyte proliferation (Santoli et al. 1990) and inhibits
TNF, IL-1 and IL-6 production by macrophages (Haynes
et al. 1992). 15-hydroxy-DGLA is an inhibitor of 5-LOX
(Iverson et al. 1991, 1992), and so can decrease the
synthesis of some ARA-derived mediators (Iverson et al.
1991, 1992). Supplementing the diet of healthy humans with
GLA results in increased PGE1 production and decreased
production of PGE2, LTB4 and LTC4 (Pullman-Moar et al.
1990; Johnson et al. 1997; Wu et al. 1999).
n-3 Polyunsaturated fatty acids and eicosanoids
Fish oil contains the long chain n-3 PUFA EPA,
docosapentaenoic acid (22:5n-3) and docosahexaenoic acid
(DHA; 22:6n-3). Feeding humans increased amounts of fish
oil results in an increase in the amount of EPA and DHA in
the membranes of cells involved in inflammation such as
Table 1. Cytokine production by spleen lymphocytes from two
different stains of mice
Concentration (pg/ml)
Mouse strain IL-2 IFN-g IL-4 IL-10
C57Bl/6 660 (60) 510 (15) 92 (10) 72 (10)
Balb/c 1100 (50)* 35 (5)* 275 (25)* 170 (15)*
Spleen lymphocytes from male C57Bl/6 and Balb/c mice (weighing approxi-
mately 24 g) were prepared by standard techniques and were cultured for
48 h in the presence of 2:5mg/ml Con A. Cytokine concentrations in the
culture supernatants were measured by specific ELISA. Data are mean
(SEM) for four separate cell preparations and are previously unpublished.
*Indicates significantly different from C57B1/6.
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monocytes, macrophages, neutrophils and lymphocytes
(Lee et al. 1985; Endres et al. 1989; Sperling et al. 1993;
Gibney and Hunter, 1993; Caughey et al. 1996; Kelley
et al. 1999; Yaqoob et al. 2000; Healy et al. 2000) (Table
3). In parallel with this there is a decrease in the ARA
content of cell membranes (Table 3). This means that there
is less substrate available for synthesis of eicosanoids from
ARA. Furthermore, EPA competitively inhibits the
metabolism of ARA. Thus, fish oil feeding results in a
decreased capacity (by 40–75 %) of immune cells to
synthesise eicosanoids from ARA (Lee et al. 1985; Endres
et al. 1989; Meydani et al. 1993; Sperling et al. 1993;
Table 2. Variation in lymphocyte responses among healthy adult humans
Subjects
Thymidine incorporation
(cpm/well)†
IL-2 production
(pg/ml){
NK cell activity
(% Cytolysis)*
Males aged 18 to 40 y; n  48 48722 (38742, 57277) 453:6 (344:4, 848:4) ND
Males aged 18 to 40 y; n  72 30071 (25056, 37260) 260:4 (176:4, 428:4) ND
Males aged 21 to 44 y; n  15 25622 (16398, 29760) 219:2 (94:1, 484:0) 29:5 (19:9, 56:1)
Males aged 46 to 71 y; n  20 18458 (13837, 21362) 297:3 (136:0, 384:1) 38:8 (28:6, 53:9)
Males aged 55 to 75 y; n  24 16729 (11802, 20681) 579:6 (361:2, 1075:2) 32:9 (27:0, 45:0)
Females aged 56 to 75 y; n  23 18089 (11532, 20304) 453:6 (226:8, 680:4) 27:4 (18:6, 38:0)
Data are the median values observed in various studies carried out by the authors; values in parentheses indicate the 25th
and 75th centiles. †Determined over the final 18 h of a 66 h period of culture of MNC in the presence of 15mg/ml Con A.
{Determined (by enzyme-linked immunosorbant assay) in the culture medium after 24 h of culture of MNC in the pre-
sence of 15mg/ml Con A. *Determined as lactate dehydrogenase release from K562 target cells over 4 h at a MNC to
K562 cell ratio of 100:1. ND indicates not determined. Data are previously unpublished in this form.
Fig. 3. Synthesis of eicosanoids from different precursor fatty acids.
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Caughey et al. 1996). A recent study reported that 6 g DHA
per day resulted in a 60 % decrease in PGE2 production and
a 75 % decrease in LTB4 production (Kelley et al. 1999);
whether this is due to DHA itself or due to retroconversion
of DHA to EPA is not clear from the data provided. ALNA
is the precursor of EPA. Caughey et al. (1996) reported
that 13:7 g ALNA per day resulted in a 33 % decrease in ex
vivo PGE2 production by human MNC; this is most likely
due to the conversion of ALNA to EPA. In addition to
competitively inhibiting the metabolism of ARA to
eicosanoids, EPA is able to act as a substrate for both
COX and 5-LOX (Fig. 3), giving rise to derivatives which
have a different structure from those produced from ARA
(i.e. 3-series PG and 5-series LT). Thus, the EPA-induced
suppression in the production of ARA-derived eicosanoids
is believed to be mirrored by an elevation in the production
of EPA-derived eicosanoids. Although this has been clearly
demonstrated by Lee et al. (1985) and Sperling et al.
(1993), who showed that dietary fish oil results in
significantly increased generation of the 5-LOX products
of EPA by stimulated neutrophils and monocytes, the
production of 3-series PG by human cells after fish oil
feeding has not been demonstrated. The eicosanoids
produced from EPA are considered to be less biologically
potent than the analogues synthesised from ARA, although
the full range of biological activities of these compounds
has not been investigated.
Influence of the amount of fat in the diet on lymphocyte
functions
Animal feeding studies
Many studies have compared the effects of feeding
laboratory animals low and high fat diets upon lymphocyte
proliferation and NK cell activity (see Calder, 1998a for
references). Such studies have often found that high fat diets
result in diminished lymphocyte functions compared with
low fat diets, but the precise effect depends upon the exact
level of fat used in the high fat diet and its source. The DTH
response was reduced after feeding high fat, compared with
low fat, diets (Friend et al. 1980; Crevel et al. 1992). These
data indicate that a high fat diet diminishes lymphocyte
activities and the cell-mediated immune response.
Human studies
A reduction in total dietary fat intake (from 41 % to 25 % to
31 % of total energy) enhanced blood lymphocyte
proliferation in response to Con A or PHA by about
200 % (Kelley et al. 1989, 1992). NK cell activity was
increased by 50 % by a reduction in fat intake from 30 % to
an average of 22 % of total energy (Barone et al. 1989;
Hebert et al. 1990). In these latter studies the reduction in fat
intake was achieved without altering the fatty acid
composition of the diet. These studies suggest that human
lymphocyte responses can be enhanced by decreasing the
amount of fat in the diet. In contrast, reducing fat intake of
elderly Danish subjects from 40 to 29 % energy did not
affect NK cell activity (Rasmussen et al. 1994), although in
this study the reduction in total fat intake was accompanied
by an increased contribution of linoleic acid and of n-3
PUFA to dietary fat.
Influence of the type of fatty acid in the diet on
lymphocyte functions
The influence of saturated fatty acids, oleic acid (18:1n-9),
linoleic acid, ALNA, ARA and the long chain n-3 PUFA,
EPA and DHA, on the functions of lymphocytes and antigen
presenting cells, on cytokine production by these cells and
on adhesion molecule expression and cell–cell interactions
has been reviewed elsewhere in detail (Calder, 1995,
1996a,b, 1997, 1998a,b,c). Thus, these effects will be
summarised here; data from new studies and for fatty acids
whose effects were not described previously will be
described in detail.
Saturated fatty acids
In vitro and animal feeding studies suggest that saturated
fatty acids have limited impact on lymphocyte proliferation,
Th1-type and Th2-type cytokine production and NK cell
activity (see Calder, 1995, 1996b, 1998a,c). The lack of
effect of varying the intake of saturated fatty acids on NK
cell activity is supported by human studies (Hebert et al.
1990; Rasmussen et al. 1994).
Oleic acid
In vitro and animal feeding studies show that oleic acid in
sufficient amounts can partially inhibit lymphocyte
proliferation, IL-2 production, IL-2 receptor and adhesion
molecule expression and NK cell activity (see Calder, 1995,
1996a, 1998a,c). These observations suggest that dietary
oleic acid has the potential to modulate lymphocyte
functions, although the contribution of oleic acid to the
animal diets in these studies was greatly in excess of the
contribution to the diet of free living humans. Yaqoob et al.
(2000) included a group who supplemented their habitual
diet with an extra 9 g of olive oil/day for 12 weeks. This had
no effect on lymphocyte proliferation, NK cell activity, or
production of TNF-a, IL-1a, IL-1b, IL-2, or IFN-g by
Table 3. Fatty acid composition of human mononuclear cells after
supplementation of the diet with evening primrose oil or fish oil
Fatty acid (g/100 g of total fatty acids)
Evening primrose oil Fish oil
Fatty acid Before After Before After
DGLA 1:2 (0:4) 2:2 (0:4)* 1:3 (0:5) 1:9 (0:5)
ARA 20:6 (2:1) 21:2 (0:5) 22:3 (0:8) 18:8 (1:3)*
EPA 1:0 (0:3) 1:1 (0:4) 0:8 (0:4) 2:8 (0:2)*
DHA 2:7 (0:4) 2:6 (0:4) 1:9 (0:5) 3:3 (0:3)
Healthy volunteers supplemented their diet with 9 g evening primrose oil (pro-
viding 1 g GLA) per day or with 9 g fish oil (providing 3:2 g EPA plus DHA)
per day for 8 weeks. Mononuclear cells were isolated by standard tech-
niques and the fatty acid composition determined. Data are mean (SEM) for
six subjects per group and are taken from Yaqoob et al. (2000). *Indicates
significantly different from before supplementation.
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MNC. One study of the effect of dietary intervention with
oleic acid upon human lymphocyte functions has been
performed (Yaqoob et al. 1998). In this study healthy free
living subjects increased their oleic acid intake from 11 % to
18 % of energy at the expense of saturated fatty acids. After
two months there was a non-significant reduction in NK cell
activity and lymphocyte proliferation, and the number of
MNC expressing CD54 was significantly decreased
(Yaqoob et al. 1998).
Linoleic acid
In vitro and animal feeding studies have shown that linoleic
acid in sufficient amounts can partially inhibit lymphocyte
proliferation, production of IL-2, CTL activity, NK cell
activity and the production of IgG and IgM (see Calder,
1995, 1996a, 1998a,c). The DTH response was lower after
feeding n-6 PUFA-rich diets compared with saturated fat-
rich or low fat diets. These observations suggest that high
levels of linoleic acid in the diet impair the cell-mediated
and antibody responses. However, more modest changes in
the amount of linoleic acid in the rat diet did not markedly
affect lymphocyte proliferation or NK cell activity (Jeffery
et al. 1997).
Surprisingly few human studies have investigated the
immunological impact of linoleic acid. The most detailed of
the studies which have been performed are those of Kelley
et al. (1989, 1992), which involved providing volunteers
with low fat diets (25 % energy as fat) which were rich in
linoleic acid (12:9 % of energy) or poor in linoleic acid
(3:5 % of energy). No differences were observed in the
responses of lymphocytes to various T-cell mitogens, in
circulating IgM, IgG, IgE or IgA levels, or in the DTH
response to seven recall antigens. Yaqoob et al. (2000)
included a group who supplemented their habitual diet with
an extra 9 g of sunflower oil/day for 12 weeks. This had no
effect on lymphocyte proliferation, NK cell activity, or
production of TNF-a, IL-1a, IL-1b, IL-2, or IFN-g by
MNC. These studies suggest limited impact of linoleic acid
(at levels between 3:5 and 12:9 % of dietary energy) upon
human immune function. However, in another study, the
low fat diet induced increase in human NK cell activity
(Barone et al. 1989; Hebert et al. 1990) was reversed by
adding 15 g safflower oil/day to the diet for 2 months
(Hebert et al. 1990); in this study linoleic acid contributed
about 8:2 % of dietary energy when the subjects were
consuming the safflower oil supplement. Furthermore, the
NK cell activity of blood lymphocytes from elderly Danish
subjects correlated negatively with linoleic acid intake and
with serum levels of linoleic acid (Rasmussen et al. 1994);
unfortunately this paper does not provide the data for
linoleic acid intakes among the subjects.
Conjugated linoleic acid
Cook et al. (1993) reported that including conjugated
linoleic acid (CLA) in the diet of chickens (0:5 g/100 g diet)
increased lymphocyte proliferation in response to T-cell
mitogens. More recent studies have reported some
immunological effects of feeding a mixture of isomers of
CLA to laboratory rodents. These studies have employed a
fairly low fat diet (5 % fat by weight) in which CLA
comprised 20 % of fatty acids present. Feeding this diet to
mice increased lymphocyte proliferation and IL-2
production but did not affect NK cell activity (Hayek et al.
1999), while feeding it to rats decreased TNF-a and IL-6
production by macrophages (Turek et al. 1998). It is unclear
which CLA isomers are responsible for these effects. At the
time of writing no studies of the influence of CLA on human
immune function have been published.
g-Linolenic and di-homo-g-linolenic acids
Both GLA and DGLA inhibited proliferation of cultured
human lymphocytes (Kelley & Parker, 1979; Santoli et al.
1990; deMarco et al. 1994; Purasiri et al. 1997; Zurier et al.
1999), and DGLA decreased the production of IL-2 by
human lymphocytes (Santoli et al. 1990); GLA probably
also decreases IL-2 production but this has not been studied.
GLA and DGLA inhibited production of IL-1b and of
TNF-a by human monocytes in culture (DeLuca et al.
1999). Human peripheral blood NK cell activity was
decreased after culture of the cells with GLA (Purasiri et al.
1997).
Feeding rats oils rich in GLA (e.g. evening primrose oil)
decreased lymphocyte proliferation and NK cell activity,
and decreased the expression of the IL-2 receptor and of
some adhesion molecules (CD2, CD11a, CD18, CD54,
CD62L) on the surface of lymphocytes (Yaqoob et al.
1994a,b; Sanderson et al. 1995a,b; Sanderson & Calder,
1998; Peterson et al. 1999). These observations suggest that
GLA in sufficient quantities will diminish the Th1-type
response. This is confirmed by the work of Matsuo et al.
(1996) who showed that evening primrose oil increased total
and ovalbumin-specific IgE production by spleen lympho-
cytes and increased circulating total and ovalbumin-specific
IgE levels following ovalbumin challenge to ovalbumin-
sensitised Brown Norway rats. In contrast, evening primrose
oil suppressed ovalbumin-specific IgG production by
lymphocytes, although circulating total and ovalbumin-
specific IgG levels were unaffected by diet. Thus, it appears
that GLA acts to diminish the Th1-type lymphocyte
response.
Supplementation studies using GLA-rich oils to provide
$2:4 g GLA per day in healthy human volunteers report
decreased production of TNF-a, IL-1 and IL-6 by
monocytes (Watson et al. 1993; DeLuca et al. 1999), and
decreased lymphocyte proliferation (Rossetti et al. 1997).
Recent studies providing #1 g GLA report no effect on
lymphocyte proliferation (Yaqoob et al. 2000), NK cell
activity (Yaqoob et al. 2000; Thies et al. 2001a) or
production of TNF-a, IL-1b, IL-2 or IFN-g (Wu et al. 1999;
Yaqoob et al. 2000; Thies et al. 2001b,c). These
observations suggest that a GLA intake of somewhere
between 1 and 2:4 g per day is required to exert
immunological effects in healthy humans.
Arachidonic acid
ARA increased IL-1b production by cultured human
monocytes (Baldie et al. 1993). In contrast, ARA inhibited
the proliferation of cultured lymphocytes, decreased the
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production of IL-2, and inhibited CTL degranulation (see
Calder, 1995, 1996a, 1998c). Feeding rats or mice on diets
containing significant amounts of ARA did not affect spleen
lymphocyte proliferation, IL-2 production, NK cell activity
or the graft versus host response, despite the increased
capacity of the cells to produce PGE2 (Jolly et al. 1997;
Peterson et al. 1998a). These studies suggest that even
significant amounts of ARA in the rodent diet do not
influence cell-mediated immunity.
Two studies of the influence of dietary ARA upon human
immune function have been performed. Including ARA
(1:5 g per day) as part of a low fat diet (27 % energy as fat)
for 8 weeks did not alter the proliferation of lymphocytes,
NK cell activity, the DTH response to seven recall antigens,
TNF-a, IL-1b, IL-6 or IL-2 production by MNC or the in
vivo antibody responses to immunisation with three strains
of influenza virus (Kelley et al. 1997, 1998a). ARA did
however increase production of PGE2 and LTB4 by LPS-
stimulated MNC. Supplementing the diet of healthy subjects
aged 55 to 75 years with encapsulated ARA (approximately
700 mg/day) for 12 weeks did not effect the NK cell activity,
lymphocyte proliferation or the production of TNF-a, IL-
1b, IL-6, IL-2 or IFN-g by MNC (Thies et al. 2001a,b,c).
Although these studies suggest that increasing ARA
consumption in healthy adults does not have adverse
immunological effects, the length of ARA administration in
these studies was no more than 12 weeks and the
immunological effects of ARA over a longer term are not
known.
a-Linolenic acid
In vitro and animal feeding studies indicated that ALNA
inhibits lymphocyte proliferation, the production of IL-2,
CTL activity, NK cell activity and the graft versus host
response (see Calder 1995, 1996a,b, 1998a,c). The precise
effect of ALNA on lymphocyte functions appears to depend
on the level of linoleic acid and the total PUFA content of
the diet (Jeffery et al. 1997).
A high dose of ALNA in the human diet (approximately
13 g per day for 4 weeks) decreased IL-1 and TNF
production by LPS-stimulated monocytes (Caughey et al.
1996). Adding linseed oil (providing about 15 g ALNA per
day) to a low fat diet (29 % energy from fat) resulted in a
significant decrease in human blood lymphocyte prolifer-
ation and in the DTH response to seven recall antigens after
6 weeks, but circulating antibody levels were unaffected
(Kelley et al. 1991). Supplementing the diet of healthy
subjects aged 55 to 75 years with linseed oil providing 2 g
ALNA per day did not significantly affect NK cell activity,
lymphocyte proliferation or production of TNF-a, IL-1b,
IL-6, IL-2 or IFN-g by MNC (Thies et al. 2001a,b,c). These
studies suggest that a moderate increase in ALNA intake by
healthy adults does not affect immunity, but that a marked
increase in ALNA intake can induce immunomodulatory
effects. It is not clear whether these are exerted by ALNA
itself or by EPA, a product of ALNA metabolism.
Eicosapentaenoic and docosahexaenoic acids
Since dietary fish oil leads to decreased PGE2 production, it
is often stated that it should reverse the effects of PGE2,
simply acting as a PGE2 antagonist. If this were so then
fish oil should increase the production of the classic
pro-inflammatory cytokines (TNF, IL-1 and IL-6), increase
the production of Th1-type cytokines, enhance MHC II
expression, lymphocyte proliferation and NK cell activity
and decrease IgE production by B-lymphocytes. Many
studies, especially those conducted in laboratory animals,
have demonstrated that, while in some situations fish oil
does act as a ‘PGE2 antagonist’, it often induces effects
which are the opposite to those predicted on this basis.
Thus, the situation is more complex than fish oil simply
being a PGE2 antagonist. This is because PGE2 is not the
sole mediator produced from ARA, and the range of
mediators produced has varying, sometimes opposite,
actions (see earlier). Thus, if fish oil was to act as a
‘4-series LT antagonist’ it would be expected to decrease
production of pro-inflammatory and Th1-type cytokines,
and NK cell activity. EPA itself will give rise to
eicosanoids with varying actions, some augmenting the
actions of ARA-dereived mediators and others antagonis-
ing those actions. In addition long chain n-3 PUFA may
exert a range of eicosanoid-independent effects, especially
upon intracellular signalling mechanisms. Thus, the overall
effect of fish oil feeding cannot be predicted solely on the
basis of an abrogation of PGE2-mediated effects.
In vitro studies have revealed a marked influence of long
chain n-3 PUFA on inflammatory and immune cell function.
EPA and DHA inhibited cytokine-induced cell surface
expression of MHC II on macrophages and monocytes
(Khair-el-Din et al. 1995; Hughes et al. 1996a), and
decreased the ability of human monocytes to present antigen
(tetanus toxoid) to autologous lymphocytes (Hughes &
Pinder, 1997). In culture, EPA and DHA inhibit the
production of IL-1b, TNF-a, IL-6 and IL-2, the
proliferation of lymphocytes, and NK cell activity (see
Calder 1995, 1996a,b, 1997, 1998a,b,c).
Feeding fish oil to laboratory rodents decreased MHC II
expression and diminished presentation of antigen ex vivo
(see Calder, 1996a,b, 1998a,b,c). A recent study reported
that dietary fish oil decreased expression of the IFN-g
receptor on murine macrophages and splenocytes (Feng
et al. 1999). Fish oil feeding has been reported to decrease
ex vivo production of TNF-a, IL-1b and IL-6 by rodent
inflammatory macrophages and monocytes (see Calder,
1996a,b, 1997, 1998b). These studies suggest that dietary
fish oil might diminish the cell-mediated immune response
by decreasing the activity of antigen presenting cells and by
decreasing the sensitivity of macrophages to T-lymphocyte-
derived cytokines. High levels of dietary fish oil decrease
NK cell activity, CTL activity, lymphocyte proliferation,
expression of the IL-2 receptor and adhesion molecules on
lymphocytes (see Calder, 1995, 1996a,b, 1998a,c) and the
production of IL-2 (Jolly et al. 1997; Wallace et al. 2001)
and IFN-g (Byleveld et al. 1999; Wallace et al. 2001).
Dietary fish oil decreased the DTH and graft versus host
responses compared with low fat or n-6 PUFA-rich or olive
oil-rich diets (see Calder, 1995, 1996a,b, 1998a,c). Dietary
fish oil also prolonged the survival of skin, kidney, heart or
Islets of Langerhans transplants in rodents (see Calder,
1996a,b, 1998a,c). Taken together, these studies suggest
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that fish oil induces a shift in the T-lymphocyte response
away from the Th1-type response, which is involved in cell-
mediated immunity, chronic inflammation and graft
rejection. In accordance with this, fish oil enhanced
production of IgE to ovalbumin in rats (Prickett et al.
1982). Animal studies have often used very large amounts
of fish oil in the diet: a diet in which fish oil contributes 20 %
by weight will mean that EPA plus DHA comprise up to
30 % of dietary fatty acids and up to 12 % of dietary energy.
Recent studies in rats and mice have indicated that relatively
low levels of the long chain n-3 fatty acids (EPA or DHA at
a level of 4:4 % of total fatty acids or 1:7 % of dietary
energy) are sufficient to bring about some of the effects of
fish oil, that dietary EPA and DHA both inhibit lymphocyte
proliferation and IL-2 production and that dietary EPA, but
not DHA, inhibits NK cell activity (Jolly et al. 1997;
Peterson et al. 1998a,b).
Supplementation of the diet of human volunteers with 1:6 g
EPA plus DHA per day for 3 weeks resulted in decreased
expression of MHC II (HLA-DP, -DQ and -DR) and of CD54
on the surface of blood monocytes (Hughes et al. 1996b). Fish
oil providing more than 2:4 g EPA plus DHA per day
decreased production of TNF, IL-1 and IL-6 by MNC (Endres
et al. 1989; Meydani et al. 1991; Gallai et al. 1993; Caughey
et al. 1996). One other study in which subjects consumed a low
fat diet including oily fish daily (providing 1:2 g EPA plus
DHA per day) showed decreased production of TNF, IL-1 and
IL-6 (Meydani et al. 1993). In contrast to these observations, a
number of studies which provided from 0:55 g to 3:4 g EPA
plus DHA per day have failed to demonstrate an effect of fish
oil on production of TNF, IL-1 and IL-6 (Molvig et al. 1991;
Cooper et al. 1993; Cannon et al. 1995; Schmidt et al. 1996;
Blok et al. 1997; Yaqoob et al. 2000; Thies et al. 2001c). Data
from studies investigating the influence of fish oil on human
lymphocyte functions are also conflicting. Supplementation of
the diet of healthy human volunteers with fish oil providing
2:4 g EPA plus DHA per day resulted in decreased
proliferation of lymphocytes from older (aged 51–68 years)
but not young (aged 21–33 years) women and decreased IL-2
production (Meydani et al. 1991). Molvig et al. (1991)
reported decreased lymphocyte proliferation after providing
1:7 or 3:4 g EPA plus DHA per day to men, while Gallai et al.
(1993) reported that 5:2 g EPA plus DHA per day decreased
IL-2 and IFN-g production. Providing 1:2 g EPA plus DHA to
healthy subjects aged 55–75 years resulted in decreased NK
cell activity (Thies et al. 2001a) and lymphocyte proliferation
(Thies et al. 2001b), but did not affect IL-2 or IFN-g
production (Thies et al. 2001b). Finally, inclusion of oily fish
providing 1:2 g EPA plus DHA per day in the diet of volunteers
consuming a low fat diet decreased lymphocyte proliferation,
IL-2 production and the DTH response to seven recall antigens
(Meydani et al. 1993). In contrast to these observations, there
are reports of no effect of 3:2 g EPA plus DHA per day on NK
cell activity, lymphocyte proliferation and IL-2 and IFN-g
production (Yaqoob et al. 2000) and of no effect of 4:6 g EPA
plus DHA per day on lymphocyte proliferation and IL-2
production (Endres et al. 1993). Thus, several studies indicate
that a high level of dietary fish oil can inhibit monocyte and
lymphocyte responses. Other studies indicate that more
modest addition of fish oil to the diet does not affect these
responses. However, there are a large number of studies which
fall between the extremes of ‘modest addition’ and ‘high level’
and these studies provide conflicting results. It is unclear what
the reasons for these discrepancies are, but they might be
related to different experimental protocols used, particularly
those involving cell preparation, cell culture and cytokine
assays and/or to different subject characteristics (e.g. gender,
age, habitual diet).
Some recent studies in humans have examined whether
the effects of fish oil are due to EPA or DHA. Kelley et al.
(1998b, 1999) reported the effects in males aged 20–40
years of including 6 g DHA per day in a low fat diet (30 %
energy as fat) for 90 days. There was no effect of DHA on
lymphocyte proliferation, serum IgG concentration or the
DTH response to seven recall antigens or on the serum
antibody response to immunisation with three strains of
influenza virus. NK cell activity was unaffected at day 55
but was decreased at day 90. The production of TNF-a and
IL-1b tended to decrease at day 55 but was significantly
decreased at day 80. More recently, 750 mg DHA per day
was shown not to affect NK cell activity, lymphocyte
proliferation or the production of TNF-a, IL-1b, IL-6, IL-2
or IFN-g in healthy subjects aged 55–75 years (Thies et al.
2001a,b,c). Taken together these data indicate that high
levels of DHA (e.g. 6 g per day) can mimic some of the
effects of fish oil but that lower levels (e.g. ,1 g per day) do
not exert any immunological effects in healthy adults.
Summary of the effects of fatty acids on lymphocyte
functions
It is apparent that lowering the amount of fat consumed in
the diet will enhance lymphocyte responses, although a
supply of essential fatty acids is necessary to support the
development of lymphoid organs and the responsiveness of
lymphocytes. It is also apparent that at any particular level
of fat in the diet, varying the fatty acid composition may
impact on lymphocytes. In vitro and animal feeding studies
suggest that saturated fatty acids have a limited effect on
immune function, but that unsaturated fatty acids have the
capacity to modulate lymphocyte functions and the cell-
mediated and antibody responses to challenge. Among the
unsaturated fatty acids, PUFA appear particularly potent
with GLA, DGLA, ARA, EPA and DHA all exerting fairly
similar effects in vitro upon lymphocyte proliferation, IL-2
production, and NK and CTL activities. Animal feeding
studies indicate that a high intake of oleic acid, linoleic acid,
GLA, ALNA, EPA or DHA can influence lymphocyte
function and cell-mediated immunity. The intakes of these
fatty acids used in animal studies are often greatly in excess
of those which could be achieved in free living humans, and
it appears from human studies that reasonable variation in
intakes of oleic acid, linoleic acid and ALNA probably has
limited impact on immune function. However, large long-
term differences in habitual intakes of these fatty acids
might influence immune function, and affect the incidence
of diseases that have an immunological component (e.g.
Linos et al. 1991). It is the PUFA which are habitually
consumed in small amounts (GLA, EPA, DHA) which
appear to have the more potent immunological effects. The
studies performed to date have not clearly defined the dose–
response effects for these fatty acids. However, it appears
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that the levels at which these fatty acids will influence
lymphocyte functions can be achieved only through
consumption of the pure oils. The immunological effects
of GLA and of the long chain n-3 PUFA are generally
termed as anti-inflammatory and the applications of these
effects have been described in terms of chronic inflamma-
tory diseases, allergic inflammation, acute systemic
inflammation in response to trauma and graft rejection.
Applications
Chronic inflammatory diseases
Chronic inflammatory diseases are characterised by a
dysregulated, overactive Th1-type response and often by an
inappropriate production of ARA-derived eicosanoids,
especially PGE2 and LTB4. The effects of fish oil outlined
above suggest that it might have a role in prevention and
therapy of these diseases (Fig. 4). Dietary fish oil has been
shown to have beneficial clinical, immunological and
biochemical effects in various animal models of human
chronic inflammatory diseases, including decreased inci-
dence and severity of inflammation in mice with type II
collagen-induced arthritis (Leslie et al. 1985) and less
inflammation in rat models of colitis (Wallace et al. 1989;
Vilaseca et al. 1990). It was recently reported that both EPA
and DHA suppress streptococcal cell wall-induced arthritis
in rats, but that EPA was more effective (Volker et al.
Fig. 4. Potential sites of action of n-3 PUFA in ameliorating chronic inflammatory diseases. Chronic inflammatory diseases are characterised
by a dysregulated Th1 response resulting from inappropriate recognition of self-antigen in genetically predisposed individuals. n-3 PUFA can
exert anti-inflammatory effects at several points (Ø) to induce clinical benefit.
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2000); this fits with the more potent effects of EPA than
DHA on inflammation and immunity.
There have been a number of clinical trials assessing the
benefits of dietary supplementation with fish oil in several
inflammatory diseases in humans including rheumatoid
arthritis, Crohn’s Disease, ulcerative colitis, and psoriasis
(see Table 4 for a summary). Many of the placebo-
controlled, double-blind trials of fish oil in chronic
inflammatory diseases reveal significant benefit including
decreased disease activity and a lowered use of anti-
inflammatory drugs; the evidence for a beneficial effect of
fish oil is strongest in rheumatoid arthritis (Table 4).
Asthma
ARA-derived eicosanoids such as PGD2, LTC4, D4 and E4
are among the major mediators of allergic inflammation
(Fig. 5). Although its action as a precursor to LT has
highlighted the significance of ARA in the aetiology of
allergic inflammation, a second link with this fatty acid has
been made. This is because PGE2 regulates the differen-
tiation and functions of lymphocytes (see earlier). Of
particular relevance in the context of asthma and related
IgE-mediated allergic diseases is the ability of PGE2 to
inhibit the production of the Th1-type cytokine IFN-g
without affecting the production of the Th2-type cytokines,
and to stimulate B-cells to produce IgE. These observations
suggest that PGE2 regulates the development of these
diseases (Fig. 5). As a result of this there has been
speculation that the increased intake of linoleic acid, the
precursor of ARA, which has occurred since the mid-1960s,
is causally linked to the increased incidence of asthma and
allergic diseases over this period (Hodge et al. 1994; Black
& Sharpe, 1997). Thus, a case has been made for increasing
the consumption of n-3 fatty acids by patients with IgE-
mediated allergic diseases (Fig. 5). There is some
epidemiological evidence to support a protective role of
long chain n-3 PUFA in these diseases (see Calder & Miles,
2000 for references). However, several studies of fish oil
supplementation in asthma reveal limited clinical impact,
Table 4. Summary of clinical trials of fish oil in chronic inflammatory diseases
Disease
Number
of
double-
blind,
placebo-
controlled
studies
Doses of EPA
+ DHA used
(g/day)
Duration
(weeks) Key findings Reviews
Rheumatoid
arthritis
13 1–6:4 12–52 All studies reported improvements, including reduced
duration of morning stiffness, reduced number of ten-
der or swollen joints, reduced joint pain, reduced time
to fatigue, and increased grip strength.
James & Cleland, 1997;
Geusens, 1998; Calder,
2001
Twelve studies reported improvement in at least two
clinical measures, and five studies reported improve-
ment in at least four clinical measures.
Ten studies reported decreased joint tenderness.
Three studies reported significant decrease in the use
of non-steroidal anti-inflammatory drugs.
Crohn’s 3 2:7–5:1 12–52 Two studies reported no benefit. Belluzzi & Miglio, 1998
Disease One study reported a significiant decrease in relapses.
One other study which used oily fish (100–250 g/day
for 2 years) reported a significant decrease in
relapses.
Ulcerative
colitis
4 1:8–5:4 12–52 One study reported no benefit (this study used the
lowest dose of EPA plus DHA)
Rodgers, 1998
One study reported a non-significant decrease in dis-
ease activity and a significant decrease in use of corti-
costeroids.
Two studies reported benefit including improved histo-
logical appearance of the colon, decreased disease
activity, weight gain and decreased use of predniso-
lone.
Two other open studies reported improved symptoms,
improved histological appearance of the rectal
mucosa and decreased use of prednisolone.
Psoriasis 2 1:8 8–12 One study reported significant improvement in itching,
scaling and erythema.
Ziboh, 1998
One study reported no benefit.
Three open studies (providing 10 to 18 g EPA plus
DHA per day for 6–8 weeks) reported mild to moder-
ate (two studies) or moderate to excellent (one study)
improvements in scaling, itching, lesion thickness and
erythema in the majority of patients.
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despite significant biochemical changes (e.g. reduced
4-series LT production) (see Calder & Miles, 2000 for
references). In contrast, some studies have shown significant
clinical improvements, at least in some patient groups, and
suggest that this type of approach may be useful in
conjunction with other drug- and diet-based therapies (see
Calder & Miles, 2000 for references). A very careful study
by Broughton et al. (1997) found that low n-3 PUFA
ingestion resulted in increased methacholine-induced
respiratory distress in adult asthmatics (Table 5). In
contrast, high n-3 PUFA ingestion resulted in an improved
response in more than 40 % of the subjects (Table 5); all
measures of respiratory function were markedly improved
in this group of patients who also showed elevated
appearance of the EPA-derived 5-series LT in their urine.
However, some patients did not respond to the high n-3
PUFA intake (Table 5). This study indicates that there are
patients who respond positively to fish oil intervention and
patients who are non-responders. This suggests that such
therapies should be approached cautiously until more is
understood about the interaction between fatty acid
consumption and disease activity.
Concluding remarks
Amongst the fatty acids it is the n-3 PUFA which possess
the most potent immunomodulatory activities, and amongst
the n-3 PUFA those from fish oil (EPA and DHA) are more
biologically potent than ALNA. Components of both natural
and acquired immunity, including the production of key
inflammatory mediators, can be affected by n-3 PUFA.
Animal studies indicate that diets rich in EPA plus DHA are
anti-inflammatory and immunomodulatory in vivo, although
there have been relatively few good studies in humans.
Although some of the effects of n-3 PUFA may be brought
about by modulation of the amount and types of eicosanoids
made, it is possible that these fatty acids might elicit some of
their effects by eicosanoid-independent mechanisms,
Fig. 5. Potential sites of action of n-3 PUFA in ameliorating IgE-mediated allergic diseases. ARA gives rise to mediators of allergic inflam-
mation and PGE2 inhibits the development of the Th1 phenotype and the production of IFN-g. This allows the development of the Th2 pheno-
type, with production of IL-4. IL-4 acts to reinforce the inhibition of the Th1-type response and also promotes IgE production by B cells. PGE2
acts directly on B-cells to promote IgE production. IL-5 is a mediator of allergic inflammation, while IL-10 (produced by Th2-type lymphocytes)
inhibits development of the Th1-type response (not shown). n-3 PUFA can exert anti-inflammatory effects at several points (Ø) to induce clini-
cal benefit. ÿ! indicates produces; !||| indicates regulates.
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including actions upon intracellular signalling pathways and
transcription factor activity (see Miles & Calder, 1998;
Yaqoob, 1998b). Such n-3 PUFA-induced effects may be of
use as a therapy for chronic inflammatory conditions
characterised by an overactive Th1 response, and for
disorders like asthma characterised by an overactive Th2
response. Moderate levels of ARA and DHA do not appear
to have any significant effects on human immune function,
but the effects of these fatty acids have been studied in the
short term and only in healthy adults. All studies of fatty
acids and the human immune system have used adults as
subjects and most studies have used men only or a mixture
of men and women. The only study which has used women
exclusively as subjects was that of Meydani et al. (1991); in
that study it was found that the immune system of older
women is more sensitive to fish oil than is that of young
women. This age-related difference in sensitivity to dietary
intervention may explain some of the contradictory
observations in the literature (e.g. between Yaqoob et al.
2000 and Thies et al. 2001a,b). It is clear that more needs to
be understood about the impact of n-6 and n-3 PUFA on the
human immune system and on how variations in age,
gender, ethnicity, hormone status, antioxidant status and
genetics influence sensitivity to dietary PUFA.
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